Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk factors for hyphema after intravitreal bevacizumab before trabeculectomy in neovascular glaucoma
TCTR20160826002Phase 4Recruiting
- Sponsor
- Maharaj Nakorn Chiang Mai Hospital
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of bevacizumab in neovascular glaucoma (NVG), sponsored by Maharaj Nakorn Chiang Mai Hospital. Started Sep 2016; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
neovascular glaucoma (NVG)
Beyond the preview
Go deeper on TCTR20160826002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20160826002.